A Study of Symptoms during a gastric Emptying (GE) study to Predict the Severity of Daily GI Symptoms in Patients with Indigestion (Dyspepsia)

Overview

About this study

The purpose of this study is to assess the utility of gastric emptying (GE) and symptoms during a GE study to predict the severity of daily GI symptoms in patients with functional dyspepsia.  In addition, aligned with other studies in our program, blood samples for DNA, RNA, and epigenetic markers will be collected to explore the relationship between these biomarkers and gastric emptying (GE) disturbances. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  1. Male or female patients aged 18 years and older undergoing a clinically indicated gastric emptying study, with or without an assessment of small intestinal and colonic transi
  2. Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation)
  3. Able to provide written informed consent before participating in the study
  4. Able to communicate adequately with the investigator and to comply with the requirements for the entire study

Exclusion Criteria:

  1. Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study
  2. Medications. Opiates, metoclopramide, and high doses of anticholinergic agents (eg, amitriptyline greater than 50 mg daily)
  3. Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain
  4. Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adil Bharucha, M.B.B.S., M.D.

Open for enrollment

Contact information:

Amber Galbreath

(507)538-3883

Galbreath.Amber@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available